Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;27:100780. doi: 10.1016/j.neo.2022.100780

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Cell cycle analysis of BEAS-2B and A549 after mono or combination therapy. Representative histograms and gating strategy after crizotinib w/o 2 Gy IR treatment (a) in BEAS-2B cells and (b) A549 cells. Cells counted in G0/G1 or G2/M phase after treatment with (c) alectinib w/o IR or (d) crizotinib w/o IR. Crizotinib increased number of BEAS-2B cells in G2/M phase after 1 µM + 2 Gy and 10 µM + 2 Gy (p < 0.050) and number of A549 cells after 1 / 5 / 10 µM + 2 Gy treatment compared to 2 Gy, respectively. Each value represents mean ± SD (n = 4). Significance was determined by two-tailed Mann Whitney U test * p ≤ 0.050.